

GAU/641
#5
MW
ZAP-1 CIP CON CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Y. Shoenfeld and P. Fishman
Serial No. : 09/405,050
Filed : September 27, 1999
For : IMMUNOTHERAPEUTIC METHOD OF TREATING
CANCEROUS DISEASES BY ADMINISTRATION
OF GAMMA GLOBULINS
Examiner : Not Yet Assigned
Group Art Unit : 1641

New York, New York
February 4, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the
above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but
before the mailing date of the first Office Action on the merits.

FEB 14 2000
TECH CENTER 1600/2900

In accordance with 37 C.F.R. § 1.98, submission of this Statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



S. Craig Rochester (Reg. No. 43,052)
Agent for Applicants

c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000
Fax.: (212) 596.9090

I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS,
WASHINGTON, D.C. 20231 on
February 3, 2000
[Signature]
Signature of Person Signing

FEB 14 2000
TECH CENTER 1600/2900



ZAP-1 CIP CON CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Y. Shoenfeld and P. Fishman
Serial No. : 09/405,050
Filed : September 27, 1999
For : IMMUNOTHERAPEUTIC METHOD OF TREATING
CANCEROUS DISEASES BY ADMINISTRATION OF
GAMMA GLOBULINS
Examiner : Not Yet Assigned
Group Art Unit : 1641

New York, New York
February 4, 2000

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following documents.*

* For the convenience of the Examiner, a completed Form PTO-1449, listing each document, is enclosed.

United States Patents

U.S. 4,699,783 (Terman et al.) (10/13/1987)

Foreign Patent Publications

EPO 0 163 493 (Siadak) (12/4/85)

Articles

Apffel, Charles A. et al., "Rejection of Lethal Ascites Tumors After Subcutaneous Inoculation: A Phenomenon of Antigenic Expression?", J. Nat. Cancer Inst., 39, pp. 1129-1139 (1967)

Attard, A.R. et. al., "The Use of Intravenous Immunoglobulin in Malignant Disorders", In Clinical Applications of Intravenous Immunoglobulin Therapy, P.L. Yap, ed., Churchill-Livingstone, pp. 203-229 (1992).

Beretta, G. et al., "Chemotherapy Versus Immunotherapy in the Treatment of Human Solid Tumors", In Oncogenes to Tumor Antigens, G. Giraldo et al., eds., Elsevier (1985)

Besa, Emmanuel C., "Recent Advances in the Treatment of Chronic Lymphocytic Leukemia: Defining the Role of Intravenous Immunoglobulin", Seminars in Hematology, 29, pp. 14-23 (1992)

Brunkhorst, U. et al., "Efficacy of Intravenous Immunoglobulins in Patients with Advanced HIV-1 Infection. A Randomized Clinical Study", Infection, 18, pp. 86-90 (1990)

Buckley, Rebecca H., "Long Term Use of Intravenous Immune Globulin in Patients with Primary Immunodeficiency Diseases: Inadequacy of Current Dosage Practices and Approaches to the Problem", Journal of Clinical Immunology, 2, pp. 15S-21S (1982)

Buckley, Rebecca H. et al., "The Use of Intravenous Immune Globulin In Immunodeficiency Diseases", New England Journal of Medicine, 325, pp. 110-117 (1991)

Cafiero, F. et al., "Prophylaxis of Infection with Intravenous Immunoglobulins plus Antibiotic for Patients at Risk for Sepsis Undergoing Surgery for Colorectal Cancer: Results of a Randomized, Multicenter Clinical Trial", Surgery, 112, pp. 24-31 (1992)

Coon, W.W. et al., "Experiences with Large Infusions of Gamma Globulin", American Journal of Surgery, 102, pp. 548-553 (1961)

Dwyer, John M., "Manipulating The Immune System With Immune Globulin", New England Journal of Medicine, 326, pp. 107-116 (1992)

Eibl, Martha M. et al., "Intravenous Immunoglobulin: A Review", Immunodeficiency Reviews, 1, pp. 1-42 (1989)

Forsberg, John-Gunnar et al., "Growth and Hormonal Responsiveness of Human Endometrial Carcinoma After Heterologous Transplantation to Neonatal Rats", Journal of the National Cancer Institute, 43, pp. 191-201 (1969)

Hague, R.A. et al., "Intravenous Immunoglobulin in HIV Infection: Evidence for the Efficacy of Treatment", Archives of Disease in Childhood, 64, pp. 1146-1150 (1989)

Hassig, A. "Lucky Strikes and Mishaps in the Development and Clinical Use of Human Immunoglobulins", in Immunomodulation by Intravenous Immunoglobulin, Rewald, E. and A. Morell (eds.), pp. 15-22 (1993)

Glynn, J.P. et al., "An Immunochemotherapeutic System for the Treatment of a Transplanted Moloney Virus-induced Lymphoma in Mice", Cancer Research, 29, pp. 515-520 (1969)

Moore, George E. et al., "Experimental and Clinical Adventures with Large Doses of Gamma and Other Globulins as Anticancer Agents", Surgery, 41, pp. 972-983 (1957)

Morell, A. et al., "Prophylactic and Therapeutic Use of Immunoglobulin for Intravenous Administration in Patients with Secondary Immunodeficiencies Associated with Malignancies", Pediat. Infect. Dis. J. 7, pp. S87-S91 (1988)

Mueller, B. M. and R. A. Reisfeld, "Potential of the SCID Mouse as a Host for Human Tumors", Cancer and Metastasis Reviews, 10, 193-200 (1991)

Needleman, Samuel W., "Durable Remission of Pure Red Cell Aplasia After Treatment With High-Dose Intravenous Gammaglobulin and Prednisone", American Journal of Hematology, 32, pp. 150-152 (1989)

Phillip, M.J. et al., "Effects of Coupled Tumor Specific Antigens (CTSA) on the Growth of Transplanted Tumors in C₃ H/HEJ Mice", Oncology, 33 pp. 7-11 (1976)

Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think", In Molecular Foundations of Oncology, S. Broder, ed., Williams & Wilkins (1991)

Seidman, Andrew D. et al., "Immune-Mediated Thrombocytopenia Secondary to Suramin", Cancer, 71, pp. 851-854 (1993)

Shastri, Kaushik A. et al., " Acquired Factor VIII Inhibitor With Squamous Cell Cancer of the Epiglottis", Archives of Otolaryngology - Head & Neck Surgery, 116, pp. 350-353 (1990)

Stiehm, E. Richard et al., "Intravenous Immunoglobulins as Therapeutic Agents", Annals of Internal Medicine, 107, pp. 367-382 (1987)

Weeks, Jane C., "Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia", New England Journal of Medicine, 325, pp. 81-86 (1991)

Wein, John et al., "Influence of Antisera from Histoincompatible Mice on Electrophoretic Mobility of EL4 Tumor Cells", Cancer Research, 27, pp. 1066-1072 (1967)

Xie, X et al., "Comparative Studies Between Nude and SCID Mice on the Growth and Metastatic Behavior of Xenografted Human Tumors", Clin. Exp. Metastasis, 10, 201-210 (1992)


The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group, "Intravenous Immune Globulin for the Prevention of Bacterial Infections in Children with Symptomatic Human Immunodeficiency Virus Infection", New England Journal of Medicine, 325, pp. 73-80 (1991)

NIH Consensus Conference, "Intravenous Immunoglobulin: Prevention and Treatment of Disease", JAMA, 264, pp. 3189-3193 (1990)

Each of the listed documents was either cited by or submitted to the Examiner in United States Application Serial No. 08/340,094, now United States patent 5,562,902, of which United States Application Serial No. 08/487,803, now United States patent 5,965,130, was a continuation, of which the instant application is a continuation-in-part. Therefore, pursuant to 37 C.F.R. § 1.98(d), copies of the documents are not being provided herewith. Should the Examiner require copies of any of the above-listed documents, applicants stand ready to supply them.

It is respectfully requested that these documents be (1) fully considered by the Examiner; (2) listed on a "Notice of References Cited" in this application; and (3) printed on any patent which may issue from this application.

Respectfully submitted,



Jane A. Massaro (Reg. No. 34,218)
Attorney for Applicants

S. Craig Rochester (Reg. No. 43,052)
Patent Agent for Applicants

c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000
Fax.: (212) 596.9090

I Hereby certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on

February 4, 2000
C. R. S. Smith

Signature of Person Signing